Evidence map›Paper›PMID 38909843›Full record

ArticleThe Journal of investigative dermatology2024

Melanotransferrin (MELTF, MFI2, CD228) Expression Attenuates Malignant Melanoma Progression in the A375-Luc2 Murine Metastasis Model and Human Patients.

Jana Jandova, Georg T Wondrak

Abstract read
In one paragraph

Article in The Journal of investigative dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jana JandovaDepartment of Pharmacology and Toxicology, R Ken Coit College of Pharmacy, The University of Arizona, Tucson, Arizona, USA; University of Arizona Cancer Center, The University of Arizona, Tucson, Arizona, USA.
Georg T WondrakDepartment of Pharmacology and Toxicology, R Ken Coit College of Pharmacy, The University of Arizona, Tucson, Arizona, USA; University of Arizona Cancer Center, The University of Arizona, Tucson, Arizona, USA. Electronic address: wondrak@pharmacy.arizona.edu.

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7M
Training in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7M
Targeted Prevention for Non-Melanoma Skin CancerP01CA229112 · NCI · UNIVERSITY OF ARIZONA · PI CURIEL-LEWANDROWSKI, CLARA, WONDRAK, GEORG T · 2019 to 2023
$7.1M
Repurposing Clinical ACT Antimalarials for Experimental Melanoma InterventionR01CA229418 · NCI · UNIVERSITY OF ARIZONA · PI WONDRAK, GEORG T · 2019 to 2023
$1.7M
NCI NIH HHS P01 CA229112NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA229418NIEHS NIH HHS P30 ES006694NIEHS NIH HHS T32 ES007091
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CRISPR/Cas9MelanomaMelanotransferrinMetastasisTissue transcriptomics

Identifiers

PMID38909843
PMCPMC12151493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.